Tibsovo
Nov 13, 2023
Servier’s Tibsovo Opens The Door To A New Era In The Battle Against Myelodysplastic Syndromes
Servier’s Tibsovo (ivosidenib tablets) has received an expanded indication from the FDA, allowing its utilization in patients diagnosed with relapsed or refractory myelodysplastic syndromes that exhibit an IDH1 mutation. This new approval represents the fifth for Tibsovo, which is already recognized for its efficac...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
